NCT05834270已完成不适用
Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Change in the lower urinary tract symptoms
研究概览
简要总结
Single dose versus double dose tamsulosin in Management of Moderate and severe lower urinary tract symptoms due to benign prostatic hyperplasia
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •age more than 50 years
- •moderate to severe lower urinary tract symptoms
排除标准
- •prostatic cancer
- •urethral stricture
- •prostate surgery
- •Neurogenic bladder
研究组 & 干预措施
Single dose tamsulosin 0.4mg
Active Comparator
Single dose tamsulosin 0.4mg
干预措施: Single dose tamsulosin 0.4mg (Drug)
Double dose tamsulosin 0.4mg
Active Comparator
Double dose tamsulosin 0.4mg
干预措施: Double dose tamsulosin 0.4mg (Drug)
结局指标
主要结局
Change in the lower urinary tract symptoms
时间窗: 3 months
Assessed by the improvement in the internal prostatic symptoms score (IPSS)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Tamsulosin effect on the treatment of urinary tract obstruction symptoms in womeIRCT20230501058042N1Sabzevar University of Medical Sciences70
Unknown
3 期
The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile DysfunctionErectile DysfunctionBenign Prostatic HyperplasiaNCT02862483IlDong Pharmaceutical Co Ltd330
已完成
3 期
Effect of Tamsulosin vs Tadalafil on ureteric and renal stone clearance in patients receiving shock treatmentCTRI/2018/01/011217Christian Medical College and Hospital Vellore250
已完成
1 期
CKD-397 Drug-drug Interaction Study (A)HealthyNCT02247518Chong Kun Dang Pharmaceutical16
尚未招募
不适用
Efficacy of a single drug versus a combination of drugs for treatment of Prostate enlargementCTRI/2021/02/031321Dr Shruti Pandit